1. Home
  2. LGIH vs NTLA Comparison

LGIH vs NTLA Comparison

Compare LGIH & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$58.16

Market Cap

1.3B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$12.45

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LGIH
NTLA
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
LGIH
NTLA
Price
$58.16
$12.45
Analyst Decision
Hold
Buy
Analyst Count
5
23
Target Price
$75.90
$20.02
AVG Volume (30 Days)
295.5K
3.4M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
1.25
N/A
Revenue
$1,705,504,000.00
$67,671,000.00
Revenue This Year
$2.32
N/A
Revenue Next Year
$17.94
$62.75
P/E Ratio
$46.53
N/A
Revenue Growth
N/A
16.92
52 Week Low
$33.55
$7.95
52 Week High
$69.42
$28.24

Technical Indicators

Market Signals
Indicator
LGIH
NTLA
Relative Strength Index (RSI) 51.47 51.07
Support Level $55.45 $11.55
Resistance Level $62.97 $15.52
Average True Range (ATR) 2.22 0.60
MACD -0.10 0.23
Stochastic Oscillator 46.38 63.84

Price Performance

Historical Comparison
LGIH
NTLA

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: